crizotinib + sorafenib

Crizotinib + sorafenib is a combination of two small molecule kinase inhibitors used primarily in oncology research. Crizotinib is a tyrosine kinase inhibitor targeting anaplastic lymphoma kinase (ALK), ROS1, hepatocyte growth factor receptor (c-MET), and Recepteur d’Origine Nantais (RON). It is approved for the treatment of ALK-positive or ROS1-positive non-small cell lung cancer, as well as ALK-positive anaplastic large cell lymphoma and inflammatory myofibroblastic tumor[5][6]. Sorafenib is a multikinase inhibitor that targets cell surface tyrosine kinase receptors and downstream kinases involved in tumor proliferation and angiogenesis, including RAF kinases, VEGFR, PDGFR, c-KIT, FLT-3, and RET. It is approved for unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and differentiated thyroid carcinoma[4][8]. The combination has been studied preclinically for synergistic antitumor effects; co-delivery in animal models showed reduced tumor development and improved survival compared to single agents[2][3].

Brand names

Nexavar

Other names

crizotinib + sorafenib